What is the price-to-earnings ratio of Pathfinder Cell Therapy?
The price-earnings ratio of Pathfinder Cell Therapy is currently -4.79.
Pathfinder Cell Therapy P/E 2024
Pathfinder Cell Therapy P/E
-4.79
Ticker
PFND
ISIN
US70319A1060
WKN
A0EAT6
As of Jul 2, 2024, Pathfinder Cell Therapy's P/E ratio was -4.79, a 22.51% change from the -3.91 P/E ratio recorded in the previous year.
The Pathfinder Cell Therapy P/E history
Pathfinder Cell Therapy Aktienanalyse
What does Pathfinder Cell Therapy do?
Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years. Pathfinder Cell Therapy ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Pathfinder Cell Therapy's P/E Ratio
The Price to Earnings (P/E) Ratio of Pathfinder Cell Therapy is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Pathfinder Cell Therapy's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Pathfinder Cell Therapy is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Pathfinder Cell Therapy’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Pathfinder Cell Therapy Stock
How has the price-earnings ratio of Pathfinder Cell Therapy changed compared to last year?
The price-to-earnings ratio of Pathfinder Cell Therapy has increased by 22.51% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Pathfinder Cell Therapy high compared to other companies?
Yes, the price-to-earnings ratio of Pathfinder Cell Therapy is high compared to other companies.
How does an increase in the price-earnings ratio of Pathfinder Cell Therapy affect the company?
An increase in the price-earnings ratio of Pathfinder Cell Therapy would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Pathfinder Cell Therapy affect the company?
A decrease in the price-earnings ratio of Pathfinder Cell Therapy would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Pathfinder Cell Therapy?
Some factors that influence the price-earnings ratio of Pathfinder Cell Therapy are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Pathfinder Cell Therapy pay?
Over the past 12 months, Pathfinder Cell Therapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pathfinder Cell Therapy is expected to pay a dividend of 0 USD.
What is the dividend yield of Pathfinder Cell Therapy?
The current dividend yield of Pathfinder Cell Therapy is .
When does Pathfinder Cell Therapy pay dividends?
Pathfinder Cell Therapy pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pathfinder Cell Therapy?
Pathfinder Cell Therapy paid dividends every year for the past 0 years.
What is the dividend of Pathfinder Cell Therapy?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pathfinder Cell Therapy located?
Pathfinder Cell Therapy is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pathfinder Cell Therapy kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pathfinder Cell Therapy from 7/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.
When did Pathfinder Cell Therapy pay the last dividend?
The last dividend was paid out on 7/2/2024.
What was the dividend of Pathfinder Cell Therapy in the year 2023?
In the year 2023, Pathfinder Cell Therapy distributed 0 USD as dividends.
In which currency does Pathfinder Cell Therapy pay out the dividend?
The dividends of Pathfinder Cell Therapy are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pathfinder Cell Therapy
Our stock analysis for Pathfinder Cell Therapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pathfinder Cell Therapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Pathfinder Cell Therapy Revenue
- Pathfinder Cell Therapy Net Income
- Pathfinder Cell Therapy P/E
- Pathfinder Cell Therapy P/S
- Pathfinder Cell Therapy EBIT
- Pathfinder Cell Therapy Dividend
- Pathfinder Cell Therapy Stocks
- Pathfinder Cell Therapy Market capitalization
- Pathfinder Cell Therapy Debt
- Pathfinder Cell Therapy Liabilities
- Pathfinder Cell Therapy Equity
- Pathfinder Cell Therapy AAQS
- Pathfinder Cell Therapy Employees
- Pathfinder Cell Therapy ROE
- Pathfinder Cell Therapy ROA
- Pathfinder Cell Therapy ROCE
